Menu
← Oncology Approval Tracker
FDA DECISION ·
Welireg + Lenvima
belzutifan with lenvatinib · Merck / Eisai
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with advanced renal cell carcinoma with a clear-cell component following a PD-1 or PD-L1 inhibitor.
LAMPGEN ANALYSIS
Why it matters
The approval gives clinicians a HIF-2α and multikinase inhibitor combination after checkpoint therapy. LITESPARK-011 tested it against cabozantinib.
What research teams should watch
Confirm histology and prior checkpoint exposure. Plan monitoring around overlapping oral-therapy responsibilities, including anemia and oxygenation for belzutifan and blood pressure for lenvatinib.
PRIMARY RECORDS